Infinity Pharmaceuticals (INFI) Set to Announce Quarterly Earnings on Tuesday

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) will post its quarterly earnings results after the market closes on Tuesday, May 3rd. Analysts expect Infinity Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) last posted its earnings results on Tuesday, March 29th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. Infinity Pharmaceuticals had a negative net margin of 2,436.06% and a negative return on equity of 122.91%. During the same quarter in the previous year, the business earned ($0.17) earnings per share. On average, analysts expect Infinity Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ INFI opened at $0.80 on Wednesday. The firm’s fifty day simple moving average is $1.00 and its two-hundred day simple moving average is $1.69. The firm has a market capitalization of $71.76 million, a P/E ratio of -1.52 and a beta of 2.08. Infinity Pharmaceuticals has a 12-month low of $0.79 and a 12-month high of $3.89.

INFI has been the topic of a number of research analyst reports. B. Riley cut their target price on Infinity Pharmaceuticals from $7.00 to $5.00 in a research report on Monday, January 24th. Piper Sandler reduced their price objective on Infinity Pharmaceuticals from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, March 29th. StockNews.com began coverage on Infinity Pharmaceuticals in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial reduced their price target on Infinity Pharmaceuticals from $12.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, March 31st. Finally, Zacks Investment Research upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $6.39.

Several large investors have recently made changes to their positions in INFI. BlackRock Inc. raised its position in Infinity Pharmaceuticals by 11.4% during the fourth quarter. BlackRock Inc. now owns 6,667,503 shares of the biotechnology company’s stock worth $15,001,000 after acquiring an additional 684,014 shares during the period. State Street Corp lifted its stake in Infinity Pharmaceuticals by 5.4% in the 4th quarter. State Street Corp now owns 1,798,973 shares of the biotechnology company’s stock valued at $4,048,000 after buying an additional 91,752 shares in the last quarter. Marshall Wace LLP boosted its holdings in Infinity Pharmaceuticals by 3,597.0% in the 4th quarter. Marshall Wace LLP now owns 600,239 shares of the biotechnology company’s stock worth $1,349,000 after buying an additional 584,003 shares during the last quarter. Nuveen Asset Management LLC increased its stake in Infinity Pharmaceuticals by 111.5% during the 4th quarter. Nuveen Asset Management LLC now owns 524,389 shares of the biotechnology company’s stock worth $1,178,000 after buying an additional 276,479 shares in the last quarter. Finally, Morgan Stanley raised its holdings in shares of Infinity Pharmaceuticals by 25.7% during the third quarter. Morgan Stanley now owns 368,291 shares of the biotechnology company’s stock valued at $1,259,000 after acquiring an additional 75,265 shares during the last quarter. Hedge funds and other institutional investors own 53.07% of the company’s stock.

Infinity Pharmaceuticals Company Profile (Get Rating)

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.

Featured Articles

Earnings History for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.